Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03513016 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee
A Phase 1 study, sponsored by Unity Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT03513016: Completed Phase 1 study, sponsored by Unity Biotechnology.
NCT03513016 is a Phase 1 study that has completed, run by Unity Biotechnology. The registered enrollment target is 78 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03513016, a Phase 1 study, has completed, sponsored by Unity Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
A study to evaluate safety, tolerability, and pharmacokinetics of a single intra-articular injection of UBX0101 in patients diagnosed with painful osteoarthritis of the knee.
Interventions
- OTHER Placebo
- DRUG UBX0101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2018-05-16 |
| Est. Completion | 2019-04-12 |
| Phase | Phase 1 |
What the finished NCT03513016 record still lists
NCT03513016 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03513016 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03513016 about?
NCT03513016 is a clinical study titled "A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee". A study to evaluate safety, tolerability, and pharmacokinetics of a single intra-articular injection of UBX0101 in patients diagnosed with painful osteoarthritis of the knee.
What is the current status of trial NCT03513016?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2018-05-16. Estimated completion is 2019-04-12.
What interventions are being tested in trial NCT03513016?
The interventions under investigation include: Placebo (OTHER), UBX0101 (DRUG).
Who is sponsoring clinical trial NCT03513016?
This trial is sponsored by Unity Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03513016's enrollment target sits among peer trials
78 697th of 2000 higher than 1,298 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI